References

Baglin TP, Keeling DM, Watson HG. Guidelines on oral anticoagulation (warfarin): third edition – 2005 update. Br J Haematol. 2006; 132:277-285
Koch-Weser J. Editorials. Ann Internat Med. 1968; 68:(6)1365-1367
Hirsh J. Oral anticoagulant drugs. New Engl J Med. 1991; 324:1865-1875
Parks ET. Lesions associated with drug reactions. Dermatol Clin. 1996; 14:(2)327-337
Porter SR, Scully C. Adverse drug reactions in the mouth. Clin Dermatol. 2000; 18:(5)525-532
Scully C, Bagan JV. Adverse drug reactions in the orofacial region. Crit Rev Oral Biol Med. 2004; 15:(4)221-239
Wright JM. Oral manifestations of drug reactions. Dent Clin N Am. 1984; 28:(3)529-543
Abdollahi M, Rahimi R, Radfar M. Current opinion on drug-induced oral reactions: a comprehensive review. J Contemp Dental Pract. 2008; 9:(3)1-15
Spyropoulos AC. Anticoagulants with Anisindione in a patient with a warfarin-induced skin eruptions. Pharmacotherapy. 2003; 23:674-677
Martin CM, Engstrom PF, Chandor SB. Skin necrosis associated with warfarin sodium. Calif Med. 1970; 113:(5)78-80
Franson TR, Maroney J. Late-onset, warfarin-caused necrosis occurring in a patient with infectious mononucleosis. Archiv Dermat. 1984; 120:(7)927-931
Shariat-Moharreri R, Khajavi MR, Ghazisaidi K. Purple toes syndrome related to warfarin therapy: a case report. Internet J Anaesthesiol. 2005; 9:(1)
Sheps SG, Gifford RW. Urticaria after administration of warfarin sodium. Am J Cardiol. 1959; 3:118-120
Adams CW, Pass BJ. Extensive dermatitis due to warfarin sodium (Coumadin). Circulation. 1960; 22:947-948

An interesting potential reaction to warfarin

From Volume 39, Issue 1, January 2012 | Pages 33-37

Authors

Grainne Mc Avinchey

BDS, MFDS

Senior House Officer, Department of Maxillofacial Surgery, Altnagelvin Area Hospital, Glenshane Road, Londonderry BT47 6SB, UK

Articles by Grainne Mc Avinchey

Brian Swinson

BDS, FDS(RCS), MBBCnBAO, AFRCSI, FRCS(OMFS)

Consultant, Department of Maxillofacial Surgery, Altnagelvin Area Hospital, Glenshane Road, Londonderry BT47 6SB, UK

Articles by Brian Swinson

Abstract

Warfarin is an oral anticoagulant, used routinely for patients with atrial fibrillation, deep vein thrombosis, pulmonary embolism and those with a mechanical prosthetic valve. There are several noted adverse reactions associated with its use, in particular the risk of haemorrhage. Other adverse reactions include: hypersensitivity, rash, alopecia, diarrhoea, unexplained drop in haematocrit, purple toes, skin necrosis, jaundice, hepatic dysfunction, nausea, vomiting and pancreatitis. In this case report, an interesting potential adverse reaction to warfarin is discussed. The reaction described affected the patient's tongue, without affecting any other aspect of the oral cavity or body.

Clinical Relevance: This case report highlights the potential problems that can be encountered by patients on warfarin therapy, specifically, the possibility for hypersensitivity type reactions.

Article

Warfarin is an oral anticoagulant used commonly in the general population. Its mode of action is to antagonize the effect of vitamin K and inhibit coagulation. It commonly takes 48–72 hours for the anticoagulant effect to develop fully and is the drug of choice for those patients with deep vein thrombosis, pulmonary embolism, atrial fibrilliation or for patients with a mechanical prosthetic valve.1

The main adverse effect associated with warfarin is the risk of haemorrhage, therefore International Normalized Ratio (INR) levels should be checked regularly and the warfarin dose adjusted accordingly.2 Other side-effects previously noted with warfarin include:

Warfarin is well known to interact with a wide array of medications, including antibiotics and antifungals, and its action can also be affected by diet, in particular foods high in vitamin K, such as liver, broccoli and green leafy vegetables. Alcohol and periods of illness, especially bacterial or viral infections, can also affect the body's response to warfarin, thereby interfering with the INR level.3 Patients should be adequately counselled before commencing warfarin therapy with regards to diet and lifestyle, and practitioners should be vigilant when prescribing other medications for such patients.

Register now to continue reading

Thank you for visiting Dental Update and reading some of our resources. To read more, please register today. You’ll enjoy the following great benefits:

What's included

  • Up to 2 free articles per month
  • New content available